The company has closed its series A round at $22.5m, with its backers including Shire, Helsinn and cancer treatment centre MD Anderson.

Ultrasound tumour treatment developer HistoSonics has been backed by Michigan’s Mints initiative and student-run Wolverine Venture Fund.

GV has led a consortium that included Osage University Partners in an overubscribed round that closed at $51.7m.

GV has led a consortium that included SR One, MRL Ventures, Lundbeckfonden Ventures and Kraft Group in an overubscribed round that closed at $51.7m.

The Yale spinout has closed an oversubscribed $80m funding round that featured Osage University Partners and Connecticut Innovations, boosting its total funding to $100m.

Sanford Health has supplied $20m in series D capital for InGeneron, which is trialling its regenerative cell therapy in its hospital network.